Skip to content
Biodatica
Start free

Investigator

Juan Fernando Vera

MARKER THERAPEUTICS, INC. · funded by NCI, FDA

Companies
2

Resolved onto their grants.

Grants
4

Federal awards on file.

Non-dilutive funding
$2.9M

Summed across those awards.

First award
Sep 15, 2022

Latest Sep 1, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R44

    A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX

    $674k

    Sep 1, 2024NCIMARKER THERAPEUTICS, INC.NIH RePORTER · 11180449 (opens the source filing in a new tab)

  2. R44

    Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy

    $1.3M

    Jun 14, 2024NCIMARKER THERAPEUTICS, INC.NIH RePORTER · 11116994 (opens the source filing in a new tab)

  3. R44

    Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant

    $665k

    Aug 10, 2023NCIMARKER THERAPEUTICS, INC.NIH RePORTER · 11181329 (opens the source filing in a new tab)

  4. R01

    Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease

    $189k

    Sep 15, 2022FDAMARKER THERAPEUTICS, INC.NIH RePORTER · 11042150 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources